Front. Cell Dev. Biol. Frontiers in Cell and Developmental Biology Front. Cell Dev. Biol. 2296-634X Frontiers Media S.A. 1292925 10.3389/fcell.2023.1292925 Cell and Developmental Biology Review Small but strong: the emerging role of small nucleolar RNA in cardiovascular diseases Sun et al. 10.3389/fcell.2023.1292925 Sun Xue 1 2 Wang Gebang 3 Luo Wenting 2 Gu Hui 2 Ma Wei 2 Wei Xiaowei 2 Liu Dan 2 Jia Shanshan 2 Cao Songying 2 Wang Yu 1 Yuan Zhengwei 2 * 1 Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China 2 Key Laboratory of Health Ministry for Congenital Malformation, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China 3 Department of Thoracic Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning, China

Edited by: Ann-Kristin Östlund Farrants, Stockholm University, Sweden

Reviewed by: Jiuwei Lu, University of California, Riverside, United States

Yongjie Xu, Xinyang Normal University, China

 *Correspondence: Zhengwei Yuan, yuanzw@hotmail.com 14 11 2023 2023 11 1292925 12 09 2023 30 10 2023 Copyright © 2023 Sun, Wang, Luo, Gu, Ma, Wei, Liu, Jia, Cao, Wang and Yuan. 2023 Sun, Wang, Luo, Gu, Ma, Wei, Liu, Jia, Cao, Wang and Yuan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Cardiovascular diseases (CVDs) are the leading cause of mortality and disability worldwide. Numerous studies have demonstrated that non-coding RNAs (ncRNAs) play a primary role in CVD development. Therefore, studies on the mechanisms of ncRNAs are essential for further efforts to prevent and treat CVDs. Small nucleolar RNAs (snoRNAs) are a novel species of non-conventional ncRNAs that guide post-transcriptional modifications and the subsequent maturation of small nuclear RNA and ribosomal RNA. Evidently, snoRNAs are extensively expressed in human tissues and may regulate different illnesses. Particularly, as the next-generation sequencing techniques have progressed, snoRNAs have been shown to be differentially expressed in CVDs, suggesting that they may play a role in the occurrence and progression of cardiac illnesses. However, the molecular processes and signaling pathways underlying the function of snoRNAs remain unidentified. Therefore, it is of great value to comprehensively investigate the association between snoRNAs and CVDs. The aim of this review was to collate existing literature on the biogenesis, characteristics, and potential regulatory mechanisms of snoRNAs. In particular, we present a scientific update on these snoRNAs and their relevance to CVDs in an effort to cast new light on the functions of snoRNAs in the clinical diagnosis of CVDs.

 biomarker cardiovascular disease heart ncRNAs SnoRNA section-at-acceptance Epigenomics and Epigenetics 1 Introduction

Cardiovascular diseases (CVDs), such as ischemic heart disease, atherosclerosis, hypertension, stroke, heart failure (HF), and peripheral arterial disease, are the leading cause of morbidity and mortality worldwide, contributing greatly to a reduced quality of life (Mensah et al., 2019; Yin et al., 2022). In 2019, CVDs were the underlying cause of approximately one-third of all deaths worldwide, accounting for 9.6 million and 8.9 million deaths among men and women, respectively (Roth et al., 2020). Multiple contributing factors have been reported in the pathogenesis of CVD, including genetic factors, lifestyle, dietary risks, tobacco smoking, and obesity. Although recent economic and technical advancements in medical treatment strategies have helped reduce CVD-associated mortality rates, the risk of developing CVDs still poses a severe hazard to human society. Furthermore, while many advances have been made in the prevention, diagnosis, treatment, and prognosis of CVDs, our current understanding of the signalling pathways involved in the molecular pathophysiology thereof is limited, hampering the identification of therapeutic targets for CVDs. Thus, there is an urgent need to identify molecular pathogenesis mechanisms, potential biomarkers, and new therapeutic targets for treating CVDs.

Recently, numerous studies have demonstrated that non-coding RNAs (ncRNAs) play a primary role in CVD development (Chen et al., 2020; Smani et al., 2020; Zhu et al., 2021). Therefore, studies on the mechanisms of ncRNAs are essential to advance diagnostic, preventative, and treatment efforts for CVDs. ncRNAs can be categorised as long non-coding RNAs (lncRNAs) and small non-coding RNAs (sncRNAs), the latter of which comprise microRNAs (miRNAs), transfer RNAs (tRNAs), small nuclear RNA (snRNAs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs) (Bergeron et al., 2020; Li X et al., 2021). In particular, snoRNAs are short (60–300 nucleotides) essential sncRNAs that primarily reside in the nucleolus of eukaryotic cells (Li M et al., 2021). Their localisation indicates a direct link to their conventional function: which is to guide post-transcriptional modifications and the subsequent maturation of rRNAs and snRNAs (Bergeron et al., 2020). snoRNAs can be detected stably in plasma and serum, and blood snoRNA levels indicate different disease statuses and relate to clinicopathological features, highlighting their suitability as disease biomarkers (Liao et al., 2010; Okugawa et al., 2017). Emerging evidence has demonstrated that snoRNAs have the potential to serve as biomarkers for a variety of diseases. For example, SNORA31 variations impair cortical neuron-intrinsic immunity to herpes simplex virus-1 (HSV-1) and underlie herpes simplex encephalitis (HSE), thereby providing a new genetic aetiology and immunological mechanism of HSE (Lafaille et al., 2019). Additionally, SNORD46 overexpression has been demonstrated to promote cancer cell growth, migration, and invasion (Gong et al., 2017). A plasma SNORD33 signature serves as a predictor of platinum-based chemotherapy sensitivity in patients with metastatic triple-negative breast cancer, which may have immediate translational relevance for precision platinum-based chemotherapy (Wang et al., 2022).

snoRNAs are extensively expressed in various mammalian tissues, including the brain, heart, reproductive organs, lungs, skeletal muscle, and liver (Watson et al., 2019; Fafard-Couture et al., 2021; Wei et al., 2021; Wu et al., 2022). Increasing evidence suggests that snoRNAs contribute to the development of CVDs such as congenital heart disease (CHD) (O’Brien et al., 2012), coronary heart disease (Mick et al., 2017), myocardial infarction (MI) (Hakansson et al., 2019), and HF(Hakansson et al., 2019). These reports have gained gradual acclaim by contributing to our understanding of the emerging role of snoRNAs in CVDs.

Considering this, this systematic review comprehensively collated available PubMed literature on the classification, characteristics, biogenesis, and potential regulatory mechanisms of snoRNAs in CVDs using the search terms “small nucleolar RNA,” “snoRNA,” “cardiovascular disease,” “CVD,” “heart,” “cardiac,” “RNA-seq,” and “transcriptomics” (an exhaustive list of all keywords searched can be found in the supplementary material). In particular, we present a scientific update on snoRNAs and their relevance to CVDs in an effort to cast new light on the functions of snoRNAs in the clinical diagnosis of CVDs.

 2 Classification and characteristics of snoRNAs

snoRNAs can be categorized into two main structural classes based on their structure, conserved sequence, and rRNA modification functions (Huang W et al., 2022), C/D Box snoRNA (Massenet et al., 2017; Yu et al., 2018; Baldini et al., 2021) and H/ACA Box snoRNA (Stepanov et al., 2015; Caton et al., 2018; Trucks et al., 2021). C/D Box snoRNA and H/ACA Box snoRNA families predominate and have been exhaustively researched, whereas limited literature exist on small Cajal body (CB)-specific RNAs (scaRNAs) (Deryusheva and Gall, 2013; Beneventi et al., 2021) and orphan snoRNAs (Kocher et al., 2021; Xu et al., 2021). The structural characteristics of each snoRNA type are delineated below.

2.1 C/D box snoRNA

C/D Box snoRNAs are typically 60–90 nucleotides in average length and are characterised by the presence of two conserved sequence motifs near their 5′ and 3′ termini: C Box (RUGAUGA) and D Box (CUGA), respectively (Figure 1A) (Baldini et al., 2021). The C and D Boxes comprise a kink-turn motif (k-turn) with noncanonical G-A base pairing and results in a severe bend in the axis of the double-stranded RNA molecule. The k-turn, a scaffold for the assembly of C/D Box ribonucleoproteins (snoRNPs), such as NOP56, NOP58, Fibrillarin, and SNU13 (15.5 kDa), is crucial for biogenesis and correct localisation (Figure 1B) (Massenet et al., 2017). This characteristic structure has biological significance in the processing and formation of snoRNAs, maintenance of stability, methylation modification, and localisation in the nucleolus. A second pair of C′ and D′ Boxes are localised closer to the middle of the C/D Box molecule, yet they often display lower sequence conservation than the C and D Boxes (Yu et al., 2018). The guide region (10–20 nucleotides) is found immediately upstream of the D Box and/or D′ Box, and it ensures modification specificity by base pairing with the target RNA.

Structural features of C/D Box and H/ACA Box snoRNAs and associated proteins. (A) The C/D Box snoRNA consists of a 5′ C Box (RUGAUGA), a 3′ D Box (CUGA), and the C′ and D′ Boxes located internally. (B) The C/D Box snoRNP complex consists of NOP56 (orange), NOP58 (pink), SNU13 (blue), and Fibrillarin (green) proteins. (C) The H/ACA Box snoRNA consists of ACA Box (ACA) and H Box (ANANNA) located in the 3′-end and the hinge region, respectively. (D) The H/ACA Box snoRNP complex consists of NHP2 (blue), NOP10 (pink), GAR1 (yellow), and Dyskerin (green) proteins.

 2.2 H/ACA box snoRNA

H/ACA Box snoRNAs (120–140 nucleotides) are characterised by the hallmark ‘hairpin-hinge-hairpin-tail’ secondary structure, which consists of two hairpin domains connected by single-stranded (hinge) and 3′-terminus (tail) regions (Stepanov et al., 2015). The H Box (ANANNA) and ACA Box are located close to the hairpin in the hinge and tail regions, respectively (Figure 1C) (Trucks et al., 2021). The H/ACA Box snoRNA antisense region is composed of two short (9–16 nucleotides) sequences located in the internal loops of the 5′ and/or 3′ hairpins. Typically, a bulge on the hairpins forms the pseudouridylation pocket, and these regions harbour complementarity with target RNAs. The H/ACA Box forms a snoRNP with Dyskerin (pseudouridine synthase), NHP2, NOP10, and GAR1 (Figure 1D) (Caton et al., 2018). Dyskerin directly promotes pseudouridylation, whereas NOP10 and NHP2 contribute to the stability and function of H/ACA Box snoRNAs. Moreover, GAR1 enhances the catalytic activity of Dyskerin and facilitates the release of the target RNA. This characteristic structure is essential for snoRNA biogenesis, stability, and localisation.

 2.3 scaRNA

Another subfamily of snoRNAs, namely, scaRNAs, is localised in the subnuclear CBs and possesses similar structural features to that of either C/D Box snoRNA, H/ACA Box snoRNA, or both. scaRNAs harbour additional nucleotide motifs, namely, GU-repeat bound and CAB boxes (UGAG), that function as CB localisation signals. Furthermore, scaRNAs not only have many similar functions to that of other snoRNAs, but also guide 2′-O-methylation and pseudouridylation of U1, U2, U4, and U5 snRNAs (Deryusheva and Gall, 2013). Moreover, scaRNA modification can occur in the nucleolus rather than the CB. Hence, they examine the possibility that scaRNA processing is not limited to the CB.

 2.4 Orphan snoRNA

It has been shown that numerous C/D and H/ACA Box snoRNAs, referred to as orphan snoRNAs, lack modification targets among rRNAs or snRNAs and have unknown functions (Kocher et al., 2021; Xu et al., 2021). For example, Xu et al. found that SNORD126 interacts with hnRNPK protein to regulate FGFR2 transcription, and activate the PI3K-AKT pathway (Xu et al., 2021). They confirm that SNORD126 plays a significant role in the development of hepatocellular carcinoma and propose that inhibiting SNORD126 expression could be an effective therapeutic strategy for treating hepatocellular carcinoma. This finding suggests that orphan snoRNAs have important physiological significance.

 3 Biogenesis and function of snoRNAs

snoRNAs are either directly transcribed from snoRNA genes via independent promoters, or they are encoded by intronic snoRNA genes without independent promoters (Bratkovic et al., 2020). snoRNAs serve a crucial function in the machinery of protein synthesis. The canonical functions of C/D and H/ACA Box snoRNAs are realised by respectively guiding the 2′-O-methylation and pseudouridylation of rRNA and snRNAs in a base-pair-dependent manner (Cao et al., 2018). In the past 20 years, novel snoRNAs have been discovered, and unexpected functions have been identified for previously annotated snoRNAs, which has led to the discovery of their diverse roles. Several studies suggest that snoRNAs regulate cell physiology by additional non-canonical modifications, including regulating alternative splicing (Nilsen and Graveley, 2010), adenosine-to-inosine (A-to-I) editing (Heraud-Farlow and Walkley, 2020), tRNAMet C34 methylation (Vitali and Kiss, 2019), DNA damage (Han et al., 2022), and mRNA 3′-processing (Kumar et al., 2019), guiding N4-acetylcytidine (ac4C) modifications (Jin et al., 2020), and performing snoRNA-derived RNA (sdRNA) functions (Wajahat et al., 2021) (Figure 2). Below, we review some of the key functions of snoRNAs by focussing on their mechanism of action.

The diverse functions of snoRNAs. An overview of the diverse functions of snoRNAs that are described in the text. The two canonical functions of snoRNAs are realised by guiding the 2′-O-methylation (A) and pseudouridylation (B) of rRNA and snRNA (red). (C) Orphan snoRNAs play key roles in alternative splicing. (D) snoRNAs may be involved in A-to-I RNA editing. (E) snoRNAs play a role in 18S rRNA acetylation. (F) SNORD97 snoRNA and its CB-specific functional homologue, SCARNA97, can direct 2′-O-methylation of the wobble cytidine C34 of human elongator tRNAMet (CAT) in a cooperative fashion. (G) snoRNAs can be processed to generate snoRNA-derived RNAs (sdRNAs), which have been shown to perform a regulatory function similar to that of miRNAs or piRNAs. (H) snoRNAs are enriched in chromatin, which affects DNA damage and genomic stability. (I) Specific snoRNAs physically associated with the mRNA 3′-end processing complex, affecting the targeting of polyadenylation sites.

 3.1 Canonical functions of snoRNA 3.1.1 2′-O-methylation

When active in its dimeric form, C/D Box snoRNA guides 2′-O-methylation of target rRNAs (Figure 2A) (Cao et al., 2018). Specifically, snoRNAs form a double helix by binding a complementary sequence in rRNA, and the nucleotide opposite the fifth nucleotide is always placed upstream of the snoRNA D or D′ Boxes. Fibrillarin is an important component of snoRNPs that transfers the methyl group from S-adenosyl methionine (SAM) to the 2′-hydroxyl group in the target RNA (Dennis et al., 2015). 2′-O-methylation optimises the structure of rRNA, thereby increasing its stability (Monaco et al., 2018).

 3.1.2 Pseudouridylation

Pseudouridylation is a highly prevalent RNA post-transcriptional modification and is guided by H/ACA Box snoRNAs (Figure 2B) (Liang and Li, 2011). This reaction, which is catalysed by the pseudouridylase Dyskerin (Garus and Autexier, 2021), maintains RNA stability and regulates ribosome synthesis (Borchardt et al., 2020). By binding to the target RNA, H/ACA Box snoRNAs convert the target uridine into pseudouridine, thereby increasing the target specificity. Additionally, pseudouridine was found to stabilise its adjacent nucleotides, which may influence the fidelity of the ribosome (King et al., 2003).

 3.2 Non-canonical functions of snoRNA 3.2.1 Alternative splicing

Alternative splicing (AS) is primarily regulated by RNA-binding proteins that bind pre-mRNAs near different splice sites to produce variably spliced mRNAs (Figure 2C) (Nilsen and Graveley, 2010). AS enriches the transcriptional output in eukaryotes and is important for gene expression (Leung et al., 2021). Different combinations of exons are created through AS to generate a variety of mRNAs, thereby increasing the variety of proteins expressed either in different tissues or in the same tissue at different intervals. Therefore, AS allows the production of mRNAs with different structures and functions, resulting in different encoded proteins (Pan et al., 2008). Chen et al. demonstrated that SNORA70E regulates the AS of PARPBP to promote the development of ovarian cancer (Chen et al., 2022). Falaleeva et al. found SNORD27 regulates the AS of the transcription factor E2F7 pre-mRNA through direct RNA-RNA interaction (Falaleeva et al., 2016). These findings suggest that snoRNAs likely affect the regulation of AS.

 3.2.2 A-to-I RNA editing regulation

A-to-I RNA editing, a unique type of post-transcriptional RNA modification, is a chemical base change that results the alteration of the primary nucleotide sequences (Heraud-Farlow and Walkley, 2020). In mammals, there are two common forms of RNA editing: A-to-I and cytidine to uridine (C-to-U). The former is catalysed by a family of enzymes called adenosine deaminases acting on RNA (ADARs) (Figure 2D) (Yang et al., 2021; Niescierowicz et al., 2022). Recent evidence indicates the capacity of A-to-I editing to modulate snoRNA precursors. Huang et al. discovered LNC-SNO49AB, a new and highly expressed snoRNA-related lncRNA that interacts with ADAR1 to enhance dimerization and increase RNA A-to-I editing rates, thereby regulating hematopoietic malignancy (Huang Z H et al., 2022).

 3.2.3 18S rRNA acetylation

As a highly conserved RNA modification catalysed by NAT10 (human) or Kre33 (yeast) (Jin et al., 2020), ac4C can be found in mRNAs, rRNAs, and tRNAs (Figure 2E). The 18S rRNA of eukaryotes contains two acetylated cytidines located in helices 34 and 45, which are crucial for translation fidelity and are part of the ribosome decoding site, respectively (Sharma et al., 2015). Sharma et al. showed that the acetylation of two N4 cytidine residues in 18S rRNA is mediated by two orphan C/D Box snoRNAs (snR4 and snR45) that direct the RNA cytidine acetyltransferase Kre33 to the target site (Sharma et al., 2017). Moreover, direct interactions between snR45 and snR4 were detected in yeast 18S rRNA using CLASH(Dudnakova et al., 2018), and the interaction of SNORD13 (the vertebrate homologue of snR45) with 18S rRNA was confirmed using PARIS (Lu et al., 2016). Bortolin-Cavaillé et al. found an atypical Drosophila melanogaster SNORD13 homologue in which a single antisense strand is sufficient for ac4C deposition, while the second may enhance the ac4C efficiency (Bortolin-Cavaille et al., 2022). Accordingly, a novel approach was revealed for reconstituting RNA-guided cytidine acetylation in human cells, thereby providing new insights into understanding and using RNA-guided RNA modification catalysts in biotechnology and disease.

 3.2.4 tRNA<sup>Met</sup> C34 methylation

tRNAs undergo a variety of post-transcriptional modifications with rich diversity, pointing their role in stabilising tRNA-mRNA interactions during decoding (Jackman and Alfonzo, 2013). Recently, Vitali and Kiss demonstrated that SNORD97 and its Cajal body functional homolog SCARNA97 (previously known as SNORD133), showing strong sequence complementarity among the two snoRNA guide regions and the tRNAMet (CAT) around the wobble cytidine C34, which was directed to be 2′-O methylated (Figure 2F) (Vitali and Kiss, 2019). Moreover, 2′-O-methylation of C34 inhibited tRNAMet (CAT) into tRNA fragments (tRFs) via the stress-responsive endoribonuclease angiogenin. This implies a regulatory connection between RNA-directed tRNA modification and angiogenin-mediated tRF processing (Nostramo and Hopper, 2019). It might be a new insight to discovery of tRNA instead of rRNA or snRNA as snoRNA and scaRNA targets; however, likely only the tip of the iceberg and further in-depth investigation is required to comprehensively elucidate this connection.

 3.2.5 snoRNA-derived RNAs

Using RNA-seq analyses, numerous groups have reported the fragmented profiles of several snoRNAs. These fragments can be processed to generate small lineage-specific conserved and functional RNAs, namely, sdRNAs (Figure 2G) (Wajahat et al., 2021; Coley et al., 2022b). These sdRNAs have miRNAs or piRNAs characteristics, which widen the functional roles of snoRNAs in a biological context. The first report of this identified that snoRNA ACA45 is processed by Dicer into small RNAs (Ender et al., 2008). These small RNAs have miRNA-like functions through which they target CDC2L6. This clearly demonstrated the cytoplasmic role of snoRNA derivatives. Additionally, in TCGA prostate cancer (PCa) patient samples, Coley et al. discovered 38 specifically excised, differentially expressed sdRNAs, which sdRNA-A24 and sdRNA-D19b were the most differentially expressed among the different fragments (Coley et al., 2022a). Therefore, they believed that these sdRNAs could potentially serve as new Pca biomarkers and therapeutic targets. Moreover, He et al. demonstrated that a Growth Arrest Specific 5 (GAS5)-derived piRNA induced H3K4 methylation/H3K27 demethylation to upregulate the transcription of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) (He et al., 2015). However, the precise mechanisms and functionality of sdRNAs remain to be elucidated.

 3.2.6 Regulation of DNA damage

Chromatin-associated RNAs (caRNAs) are a recently identified class of RNA molecules that are linked to chromatin transcription. Moreover, caRNAs are involved in a variety of biological processes, including the regulation of genes, chromatin structure, cell division, and cell specification (Diermeier et al., 2014). Recent evidence has shown that a fraction of snoRNAs is enriched in caRNAs from human and Drosophila cells, forming an RNP complex that may play a role in eukaryotic chromatin biology. For example, Schubert et al. indicated that snoRNAs are associated with Drosophila chromatin-binding protein (Df31), which plays a role in maintaining open chromatin structure (Schubert et al., 2012). Another study found that snoRNA bind poly ADP-ribose polymerase 1 (PARP1) to stimulate PARP-1 ADPRylates DDX21 in cells to promote cell proliferation (Kim et al., 2019). Han et al. found that SNORA73, which is enriched in chromatin, suppressed PARP1 auto-PARylation by forming a non-canonical snoRNP with PARP1 and the canonical partners DKC1/NHP2 to affect DNA damage and genome stability (Figure 2H) (Han et al., 2022). Mechanistically, SNORA73’s 5′ non-canonical structure is essential for its function and PARP1 binding. Their findings emphasised the potential chromatin-associated functions of snoRNAs and provided novel insights into the functional diversity of snoRNAs in cells.

 3.2.7 Regulation of mRNA 3′-end processing

mRNA 3′-end processing occurs cotranscriptionally and is an essential step in gene expression (Kumar et al., 2019). Huang et al. found a subset of snoRNAs physically associated with the mammalian mRNA 3′-processing complex. SNORD50A is U/A-rich and specifically interacts with FIP1, thereby preventing FIP1 from interacting with poly(A) site (PAS) sequences in vitro and in vivo (Figure 2I) (Huang et al., 2017). Of note, they provided the first experimental evidence that snoRNAs may play a regulatory role; however, they are not essential in regulating mRNA 3′-end processing. Nevertheless, their findings provide novel insights into the regulatory mechanism of mRNA 3′-end processing and expand our understanding of the non-canonical functions of snoRNAs.

 4 Detection, analysis and databases of snoRNAs

snoRNAs, as a class of ncRNAs, often show heterogeneity regarding their structure, interacting proteins, RNA modification types and targeting locations. Therefore, sophisticated and collaborative profiling approachs to analyse their role are required. Numerous methods, including qPCR(Galiveti et al., 2010), RNA-seq (Wu et al., 2016), Northern blotting (Kishore et al., 2010) and RNA protection assay (RPA), are commonly utilized to analyze the expression of snoRNA at present. The snoRNA-protein interactions are promising including UV crosslinking and immunoprecipitation (CLIP) (Cao et al., 2019), RNA immunoprecipitation (RIP), RNA antisense purification (RAP) (Cao et al., 2019), RNA pull-down (Li et al., 2020), and Cross-linking and analysis of cDNA (CRAC) (Cao et al., 2019) techniques. RNA hybrid and individual nucleotide resolution CLIP (hiCLIP) (Cao et al., 2019), and crosslinking, ligation, and sequencing of hybrids (CLASH) (Cao et al., 2019) methods are used to analyze the RNA-RNA interactions.

For future studies on snoRNAs, several databases can be used such as snoRNABase, snoRNA Atlas, snoPY, and snoDB (Bergeron et al., 2023). Researchers can use to analyze snoRNA sequences, features, host gene, chromosomal location, average abundance, snoRNA-RNA targets, and snoRNA orthology relationships to fill gaps in snoRNA research.

 5 Role of snoRNAs in CVD

Previous researches on the biological roles of regulating snoRNAs have primarily focused on the development of various cancers (Mourksi et al., 2020; Ding et al., 2021; Zhu et al., 2022). Nevertheless, snoRNAs have many characteristics, especially tissue or cell specificity. In recent studies, snoRNAs have been found in the cardiovascular tissues and are differentially expressed in patients with CVD (O’Brien et al., 2012; Mick et al., 2017; Nossent et al., 2019). These findings have revealed the essential role that snoRNAs play in cardiac development, pathophysiology, and lipid metabolism, as well as reveal their potential as both biomarkers of disease and novel therapeutic targets (Table 1) (Michel et al., 2011; Rajan et al., 2017; Das et al., 2020; Killick et al., 2022), however, the associated regulatory mechanisms have not been comprehensively investigated. Limited research exist on the functions of snoRNAs in CVDs, and to date, no systematic review has collated the broad range of topics on snoRNAs in CVDs. Therefore, we provide an extensive overview of the latest research on snoRNAs identified in a variety of CVDs (Figure 3).

The function and mechanisms of snoRNAs in cardiovascular diseases.

Disease Regulation snoRNA name Class Genomic location Host gene Target gene Mechanism/Pathway Function References
CMD Dynamically regulate U32(SNORD32A) C/D 19q13.33 RPL13A 18S rRNA Regulated by NADPH oxidase Unknown Michel et al., 2011; Holley et al., 2015
Dynamically regulate U33(SNORD33) C/D 19q13.3 RPL13A 18S rRNA Regulated by NADPH oxidase Unknown Michel et al., 2011; Holley et al., 2015
Dynamically regulate U34(SNORD34) C/D 19q13.33 RPL13A 28S rRNA Regulated by NADPH oxidase Unknown Michel et al., 2011; Holley et al., 2015
Dynamically regulate U35a (SNORD35A) C/D 19q13.33 RPL13A 28S rRNA Regulated by NADPH oxidase Unknown Michel et al., 2011; Holley et al., 2015
Dynamically regulate SNORA73A (U17a) H/ACA 1p35.3 SNHG3(U17HG) unknown Regulate HUMMR, regulate cell metabolism through mTOR pathway Unknown Jinn et al., 2015; Sletten et al., 2021
Dynamically regulate SNORA73B(U17b) H/ACA 1p35.3 SNHG3(U17HG) unknown Regulate HUMMR, regulate cell metabolism through mTOR pathway Unknown Jinn et al., 2015; Sletten et al., 2021
Dynamically regulate U60(SNORD60) C/D 16p13.3 Cluster of ESTs 28S rRNA Affecting internalization of plasma membrane cholesterol Unknown (Brandis et al., 2013)
CHD Downregulated scaRNA9 C/D Chr11 KIAA1731 U2 Unknown AS (O'Brien et al., 2012)
Downregulated scaRNA2 C/D Chr1 — U2 Unknown AS (O'Brien et al., 2012)
Downregulated scaRNA8 H/ACA Chr9 FAM29A U2 Unknown AS (O'Brien et al., 2012)
Downregulated scaRNA4 H/ACA Chr1 KIAA0907 U2 Unknown AS (O'Brien et al., 2012)
Downregulated scaRNA1 (ACA35) H/ACA Chr1/1p35.3 PPP1R8 U2 Alter pseudouridylation at U89 in U2 AS O'Brien et al., 2012; Patil et al., 2015; Nagasawa et al., 2018; Nagasawa et al., 2020
Downregulated SNORD7 C/D Chr17/17q12 Cluster of ESTs U6 Unknown AS (O'Brien et al., 2012)
Downregulated SNORD8 C/D Chr14 CHD8 U6 Unknown AS (O'Brien et al., 2012)
Downregulated SNORD9 C/D Chr14 CHD8 U6 Unknown AS (O'Brien et al., 2012)
Downregulated SNORD67 C/D Chr11 CKAP5 U6 Unknown AS (O'Brien et al., 2012)
Downregulated SNORD94 C/D Chr2 PTCD3 U6 Alter methylation at C62 in U6 AS O'Brien et al., 2012; Patil et al., 2015; Nagasawa et al., 2018; Ogren et al., 2019
Downregulated scaRNA23 H/ACA ChrX POLA1 U6 Unknown AS (O'Brien et al., 2012)
Downregulated scaRNA9L C/D ChrX EIF1AX U2 Unknown AS (O'Brien et al., 2012)
HF Upregulated SNORD112 C/D 14q32 MEG8 Unknown Unknown Unknown (Hakansson et al., 2019)
Upregulated SNORD113-2 C/D 14q32 MEG8 Unknown Unknown Unknown (Hakansson et al., 2019)
Upregulated SNORD113-6 C/D 14q32 MEG8 Unknown Unknown Unknown (Hakansson et al., 2019)
Upregulated SNORD113-8 C/D 14q32 MEG8 Unknown Unknown Unknown (Hakansson et al., 2019)
Upregulated SNORD114-1 C/D 14q32 MEG8 Unknown Unknown Unknown (Hakansson et al., 2019)
MI Upregulated SNORD113-2 C/D 14q32 MEG8 Unknown Unknown Unknown (Hakansson et al., 2019)
PAD Upregulated SNORD112 C/D 14q32 MEG8 Unknown Unknown Unknown (Nossent et al., 2019)
Upregulated SNORD113-2 C/D 14q32 MEG8 Unknown Inverse correlations with leukocyte counts, active smoking and platelet activation Unknown (Nossent et al., 2019)
Upregulated SNORD 113-6 C/D 14q32 MEG8 Unknown Unknown Unknown (Nossent et al., 2019)
Upregulated SNORD 114-1 C/D 14q32 MEG8 Unknown Inverse correlations with leukocyte counts, active smoking and platelet activation Unknown Håkansson et al., 2018; Nossent et al., 2019
HCM Upregulated SNORD96A C/D 5q35.3 GNB2L1 5.8S rRNA Unknown PTMs and AS (James et al., 2021)
Upregulated SNORD73A C/D 4q31.3 RPS3A 28S rRNA Unknown PTMs and AS (James et al., 2021)
Upregulated SNORA12 H/ACA 10q24.31 CWF19L1 Unknown Unknown Unknown (James et al., 2021)
Upregulated SNORD3A C/D 17p11.2 — Unknown Unknown Unknown (James et al., 2021)

AS, alternative splicing; CHD, congenital heart disease; CMD, cardiometabolic disease; HCM, hypertrophic cardiomyopathy; HF, heart failure; MI, myocardial infarction; PAD, peripheral artery disease; PTM, post translational modifications.

List of snoRNAs that differentially expressed in cardiovascular diseases. The dysregulation of snoRNAs contributes to the progression of various cardiovascular diseases, including cardiometabolic disease, coronary heart disease, congenital heart disease, myocardial infarction, vascular remodelling and peripheral artery disease, heart failure and hypertrophic cardiomyopathy.

 5.1 Role of snoRNAs in cardiometabolic disease

Cardiometabolic diseases (CMDs) are a group of metabolic abnormalities that increases the risk of CVDs and type 2 diabetes mellitus (T2DM), in addition to pathological changes such as hypertension, hyperglycemia, lipid metabolism abnormalities, and environmental risk factors like poor diet, sedentary lifestyle, and smoking, which are the main causes of frailty, disability, and decreased quality of life in the older (Ash-Bernal and Peterson, 2006; Killick et al., 2022; Kim et al., 2022). Several studies have investigated the function of snoRNAs in CMDs, including diabetes mellitus, lipid metabolism abnormalities, and doxorubicin cardiotoxicity (Michel et al., 2011; Amri and Scheideler, 2017; Schaffer, 2020). The first of these studies found that the loss of three snoRNAs (U32a, U33 and U35a) from the ribosomal protein L13a (RpL13a) locus conferred in vitro resistance to lipotoxic and oxidative stress and prevented the in vivo propagation of oxidative stress (Michel et al., 2011). These snoRNAs are not only important oxidative stress regulators, but also perform a physiological function in increasing oxidative stress in response to lipid toxicity and systemic inflammation. These findings were the first to implicate snoRNAs as regulators of metabolic stress responses in mammalian cells. Moreover, they demonstrated that RpL13a snoRNAs accumulate in the cytoplasm during lipotoxic or oxidative stress (Holley et al., 2015). Doxorubicin-induced oxidative stress is dynamically regulated by NADPH oxidase, which causes the rapid cytoplasmic accumulation of RpL13a snoRNAs during lipotoxic or oxidative stress. These findings imply that snoRNAs may coordinate the response to environmental stress through molecular interactions outside the nucleus. Lee et al. showed that the loss of RpL13a snoRNAs affected mitochondrial metabolism and reduced reactive oxygen species tone, which increased insulin secretion from pancreatic islets and improved systemic glucose tolerance (Lee et al., 2016). After inflammation, RpL13a snoRNAs have also been detected in extracellular vesicles (EVs), suggesting that they may be picked up by other cells to guide 2′-O-methylation (Rimer et al., 2018). Similarly, both SNORA73 (U17) and SONRD60 (U60) directly regulate lipid metabolism (Brandis et al., 2013; Jinn et al., 2015; Sletten et al., 2021). Furthermore, SNORA73 regulates cholesterol homeostasis of cells by inhibiting the expression of hypoxia-upregulated mitochondrial movement regulator (HUMMR). This SNORA73-HUMMR pathway may play a physiological role in gonadal tissue maturation (Jinn et al., 2015). Sletten et al. found that in vivo knockdown of SNORA73 prevents lipid-induced hepatic steatosis, oxidative stress, and inflammation (Sletten et al., 2021). These findings suggest that snoRNAs could serve as therapeutic targets for metabolic diseases. In addition, SNORD60 contributes to cholesterol homeostasis (Brandis et al., 2013). In summary, these snoRNAs may play a critical role in CMDs by affecting cholesterol metabolism, reactive oxygen species, oxidative stress, inflammation, and diabetes mellitus.

 5.2 Role of snoRNAs in CHD

CHD is a predominant birth defect that affects approximately 1.9%–7.5% of live births (Williams et al., 2019; Kruszka and Beaton, 2020; Kim, 2021; Samad and Wu, 2021). CHD contains a wide scope of heart malformations, ranging from a single abnormality (atrial septal defect or ventricular septal defect) to complicated multiple defects (hypoplastic left heart syndrome or tetralogy of Fallot) (Morton et al., 2022). Tetralogy of Fallot (TOF) is the most common cyanotic CHD (Zeng et al., 2016; Morgenthau and Frishman, 2018). Recent studies comparing the snoRNAs in the right ventricular myocardium of infants with TOF to those of normal foetal and developing infant hearts suggested that the expression of 135 snoRNAs (including 12 scaRNAs) were statistically distinct in the TOF myocardium (O’Brien et al., 2012). Most of these snoRNAs (n = 126) showed decreased expression levels in the TOF myocardium. The expression of 115 snoRNAs decreased similarly in the foetal myocardium and the control tissue. The majority of the downregulated snoRNAs targeted four ncRNAs: rRNAs 28S and 18S, and two snRNAs, namely, U2 and U6. However, the 12 scaRNAs that were substantially downregulated in the TOF myocardium targeted only U2 and U6. Furthermore, U2 and U6 exhibited lower expression levels in TOF and foetal tissues compared to those of the control. Notably, approximately 7.5% of all genes bearing U2-type intron/exon recognition sequences displayed variation in their splice forms, and nearly 51% of genes associated with heart development were alternatively spliced in TOF compared with their controls. Taken together, these results indicate a connection between the downregulated expression of scaRNAs targeting the snRNAs U2 and U6, alternative splicing, and developmental defects in infants with TOF. These novel insights into the altered expression of snoRNAs in infants with TOF suggest that snoRNAs may affect the expression of important genes, transcript splicing, and translation during development, thereby possibly leading to the development of cardiac defects. Patil et al. and Nagasawa et al. inhibited scaRNA expression in cell cultures, resulting in abnormal splicing of several genes that regulate heart development (e.g., gata4, mbnl1, and Wnt-pathway genes) (Patil et al., 2015; Nagasawa et al., 2018). This may be ascribed to the impairment of snRNA modifications as a result of the inhibited scaRNA expression. Thereafter, they targeted the knockdown of two scaRNAs (SNORD94 and scaRNA1) in zebrafish that resulted in abnormal heart development and the alteration of splice isoforms of cardiac regulatory genes. These observations strongly suggest that snoRNAs and snRNAs are necessary for normal cardiac development. Furthermore, Ogren et al. reported that methylation in the target region of SNORD94 on U6 is decreased in right ventricular myocardium tissue of infants with TOF compared with that of the control (Ogren et al., 2019). Additionally, cell culture experiments revealed that, by changing the levels of SNORD94, a corresponding change in methylation at C62 within the snRNA U6 is produced. Taken together, these findings suggest a direct relationship between scaRNA expression and target nucleotide methylation. Moreover, scaRNA influences alternative splicing of mRNA; however, further investigation is needed to comprehensively elucidate this mechanism and its underlying pathway.

Nagasawa et al. further investigated the relationship between scaRNA1 and pseudouridylation levels in snRNA U2 (Nagasawa et al., 2020). Their results showed that pseudouridylation levels were significantly decreased in the right ventricular myocardium tissue of infants with TOF compared with that of the control. Moreover knockdown of scaRNA1 levels in normal primary cardiomycytes resulted in a significant decrease of pseudouridylation. This indicates that scaRNA1 levels determine the pseudouridylation levels of uridine 89 (U89) in snRNA U2 and affect alternative mRNA splicing and embryonic development. Based on these heart development studies, we conclude that snoRNAs are important in cardiac development and CHDs.

 5.3 Role of snoRNAs in coronary heart disease

Coronary heart disease is a fatal CVD that is difficult to clinically diagnose early (Yin et al., 2021). Coronary heart disease is characterized by stenosis or occlusion of blood vessels due to coronary atherosclerosis, which impedes blood flow to the myocardium and results in myocardial ischemia, hypoxia, and necrosis (Boudoulas et al., 2016). The recent application of RNA sequencing to discover extracellular RNAs in Framingham Heart Study (FHS) participants has identified over 1,000 human extracellular RNAs (ex-RNAs), including microRNAs, snoRNAs, and piRNAs, present in biofluids (Mick et al., 2017). Moreover, an independent cohort confirmed the presence of snoRNAs in the plasma. Subsequent quantitative measurements of exRNAs in participants of the FHS were undertaken to identify possible links with coronary heart disease. In 2763 FHS participants, RT-qPCR included 331 of the most abundant miRNAs, 43 snoRNAs, and 97 piRNAs, and revealed that these was no relationship between ex-RNAs and the prevalence (n = 286) and incidence (n = 69) of coronary heart disease. Nevertheless, this was the first large study of human sncRNAs beyond miRNAs to investigate the effects of ex-RNAs in relation to coronary heart disease and stroke using an unbiased approach in an observational cohort. Further investigations are required to explore the relationship between snoRNAs and coronary heart disease.

 5.4 Role of snoRNAs in MI

MI, caused by a thrombus or coronary vascular occlusion, results in irreversible ischaemic injury in middle-aged and elderly people, but now showing a younger trend (Çakmak and Demir, 2020; Berkeley et al., 2023). MI is characterised by myocardial necrosis resulting from acute and persistent ischaemia and hypoxia of the coronary arteries (Li X et al., 2021). Additionally, MI is usually followed by cardiac remodelling, which can progress to HF in cases where the original insult is severe or prolonged (Tang et al., 2021). As a novel ncRNA, the snoRNA-mediated regulation of MI has not been systematically studied. However, Håkansson et al. reported that in a ST-elevation myocardial infarction (STEMI)–patient cohort, seven snoRNAs (SNORD112, SNORD113-2, SNORD113-6, SNORD113-7, SNORD113-8, SNORD113-9 and SNORD114-1) were detectable in plasma after hospitalisation, albeit at low levels (Hakansson et al., 2019). Furthermore, plasma SNORD113-2 was upregulated two-fold between day 4 and 30 in STEMI patients after hospitalisation. The remaining snoRNA levels showed time-dependent regulation; however, no significant changes were observed in their expression. Schena et al. demonstrated that a Cortical Bone Stem Cell-Derived Exosomes (CBSC-dEXOs) injection into the myocardial infarction region had a protective effect against ischaemia-reperfusion injury (Schena et al., 2021). They performed RNA sequencing on normal human ventricular cardiac fibroblasts (NHCFs) after human CBSC-dEXO treatment, demonstrating that cotreatment with TGFβ and exosomes decreased snoRNA levels. This may be ascribed to CBSC-derived exosomal snoRNA content reducing ribosomal stability within the treated cells, affecting protein translation and reducing fibroblast activation. However, further studies are required to confirm this hypothesis. It is well established that CVDs may lead to MI, myocardial ischaemia, and hypertrophic cardiomyopathy (HCM) (Lim et al., 2020). Therefore, in addition to evaluating the relationship between snoRNAs and MI, it may be worthwhile to determine the snoRNA-regulatory targets and signalling pathways associated with other CVDs.

 5.5 Role of snoRNAs in HF

HF is a common CVD in the elderly, which refers to the incapacity of the heart to supply blood to the body at a rate proportional to its demands, or it can only do so at the cost of high filling pressures. The main clinical manifestations are shortness of breath, fatigue, and ankle edema (Lam et al., 2023). Welten et al. recently discovered the prominent involvement of a large gene cluster of 54 miRNAs transcribed from human chromosome 14 (14q32) in CVDs. In addition to 54 miRNAs, the human 14q32 locus also encodes 3 lncRNAs and 41 snoRNAs (Welten et al., 2016). Håkansson et al. screened the 14q32 locus within a dataset of 5,244 PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) participants (Hakansson et al., 2019). Single nucleotide polymorphisms (SNPs) in the 14q32 snoRNA-cluster were associated with HF, and snoRNAs independently modulated CVD risk. Moreover, they found that, compared to naive vena saphena magna tissues and failed coronary bypasses, snoRNA expression from the DLK1-DIO3 locus on 14q32 was the highest in human end-stage HF samples. These findings demonstrated that 14q32 snoRNAs play a unique role in CVDs, and that snoRNAs merit more attention and effort in future basic and clinical cardiovascular studies.

 5.6 Role of snoRNAs in vascular remodelling and peripheral artery disease

Vascular remodelling is a multifactorial process which includes both adaptive and maladaptive alterations of the vessel wall (Gong et al., 2021). This includes processes such as angiogenesis, arteriogenesis, atherosclerosis, hypertension, and restenosis after angioplasty. Vascular remodelling can be beneficial, such as during neovascularization after ischemia. However, vascular remodelling is also the primary underlying cause of most CVDs and is a pathological process governed by genetic and environmental interactions with a complex aetiology and pathogenesis. All layers of the arterial wall, including the tunica intima composed of endothelial cells, tunica media composed of smooth muscle cells, and tunica adventitia mainly composed of fibroblasts, play their respective roles in vascular remodelling (Seidelmann et al., 2014). However, the role of adventitial fibroblasts has often been underestimated. Van Ingen et al. demonstrated that SNORD113-6/AF357425 plays a dual role in the integrin signalling pathway and arterial fibroblast function via two distinct mechanisms: pre-mRNA processing/splicing and 2′-O-methylation of mRNA targets, which has a stabilising effect on mRNA expression (van Ingen et al., 2022b). They observed that the inhibition of SNORD113-6 altered the function of human primary arterial fibroblasts, possibly as a result of changes in the integrin signalling pathway, which is crucial for fibroblast cell–cell and cell–matrix interactions. According to their latest findings, tRNAs are the predominant small RNA targets of SNORD113-6/AF357425 in primary fibroblasts (van Ingen et al., 2022a). SNORD113-6/AF357425 induced 2′-O-methylation to protect tRNALeu against site-specific fragmentation during vascular remodelling, rather than promoting it. However, the function of tRFLeu 47–64 in vascular remodelling and CVDs remains unclear. Peripheral artery disease (PAD) is caused by progressive atherosclerosis and primarily affects arteries of the lower extremities (Hiatt et al., 2008; Campia et al., 2019). In patients with end-stage PAD and elite cyclists, Håkansson et al. examined the plasma levels of a specific group of snoRNAs from the 14q32 locus (Håkansson et al., 2018). They reported that SNORD114-1 were highly expressed in patients with PAD as opposed to that in elite cyclists. They demonstrated, for the first time, that endurance exercise affects the plasma levels of SNORD114-1. Continuing this line of studies, Nossent et al. showed that the 4 snoRNAs (SNORD112, SNORD113-2, SNORD113-6, SNORD114-1) were highly expressed in the plasma of 104 patients with PAD (Nossent et al., 2019). They further evaluated the relationship between snoRNAs and diseases associated with PAD prognosis, as well as classical risk factors for PAD development and progression. These findings indicated that the plasma levels of these snoRNAs were not directly related to most of the classical risk factors of atherosclerosis and restenosis in target vessels. Strong negative associations were found between the levels of SNORD113-2 and SNORD114-1 and platelet activity, which plays a key factor in the long-term outcome of PAD and CVD.

 5.7 Role of snoRNAs in HCM

HCM is a common inheritable cardiac disorder featuring left ventricular hypertrophy (LVH) which cannot explained by other systemic, cardiac or metabolic diseases capable of leading to the degree of LVH (Desai et al., 2023). The clinical manifestation is varied with symptoms ranging from no symptoms or modest effort intolerance to severe symptoms, such as syncope or dyspnea, diastolic dysfunction, advanced HF, and sudden cardiac death. Several studies have shown that different ncRNAs play key regulatory roles in the pathophysiology of HCM (Li et al., 2019; Shahzadi et al., 2021). Accordingly, James et al. presented a transcriptomic analysis of an isogenic human-induced pluripotent stem cells (hiPSC) differentiated into cardiomyocytes (hiPSC-CMs) model of HCM (James et al., 2021). They observed differential levels of snoRNAs between wild-type (WT) and HCM hiPSC-CM EVs. Overall, 12 snoRNAs were identified, including 2 H/ACA Box snoRNAs (SNORA3B and SNORA20) and 10 C/D Box snoRNAs (SNORD6, SNOTRD116-23, SNORD116-25, SNORD116-29, SNORD18A, SNORD42A, SNORD43, SNORD58C, SNORD60, and SNORD101). Interestingly, when HCM hiPSC-CMs were exposed to increased workload, the specifically changed. When compared to 2 Hz-stimulated WT hiPSC-CM EVs, SNORD96A and SNORD73A levels in 2 Hz-stimulated HCM hiPSC-CM EVs were significantly increased. In addition, 2 Hz stimulation was sufficient to change the snoRNA levels in the HCM hiPSC-CM EVs, including SNORA12 and SNORD3A. These snoRNAs may play an important role in post-translational modifications and alternative splicing and may be used as HCM biomarkers or RNA-targeting therapies in the future. Furthermore, Tallo et al. made a Drosophila model of feline HCM and conducted transcriptome analyses using RNA-seq (Tallo et al., 2021). They found that snoRNAs were significantly dysregulated in exercised female flies harbouring mutant alleles as opposed to flies that harboured the WT allele. Among them, 23 snoRNAs were downregulated by R820W(Arg820Trp) while upregulated by WT just in the exercised females. These findings suggest that the identified deregulated snoRNAs may play a role in the pathogenesis of HCM, especially under cardiac stress conditions.

 6 Future perspectives and conclusion

CVDs are the leading contributors to mortality and disability worldwide (Mensah et al., 2019). In current CVD treatment strategies, the emphasis is on disease prevention, early diagnosis, and individualised treatment. Although many CVD biomarkers, which facilitate diagnosis and monitoring, have been discovered and used, they are still unsatisfactory for the clinical diagnosis and treatment of CVDs. Therefore, identification of novel, sensitive, and effective biomarkers is becoming increasingly important. Currently, medical research is focussed on ncRNAs (Poller et al., 2018; Fasolo et al., 2019; Slack and Chinnaiyan, 2019), resulting in numerous studies demonstrating their functions and mechanisms and identifying potential CVD biomarkers (Chen et al., 2020; Smani et al., 2020; Zhu et al., 2021). However, the regulatory mechanisms connecting ncRNAs with CVDs are mainly unknown and require further research. Nevertheless, the imperative need to identify novel CVD biomarkers and targets has led to the discovery of snoRNAs, which shows significant potential in this area of research.

To date, studies on the complex regulatory mechanism of snoRNAs has generally focused on cancers and neurodegenerative diseases. However, the regulatory mechanisms of snoRNAs in CVDs, which is the focus of this review, have not been extensively investigated. Consequently, our summary is somewhat constrained. This review focuses specifically on several CVDs such as CHD, MI, PAD, and HF that may be potential regulated by snoRNAs. However, the involved snoRNAs and their underlying regulatory mechanisms in CVDs have not been fully elucidated, and further investigation is required. Through systematic reviews of snoRNA and CVDs, we found an interesting phenomenon that many snoRNAs, such as SNORD113 family and SNORD114 family, are differentially expressed in multiple CVDs including HF, MI, and PAD diseases. These interesting overlaps lead us to speculate that some snoRNA families may play important roles in different CVDs, which also indicates that snoRNA may have great potential space in the study of CVDs. At present, snoRNA can achieve promising results through RNA-seq and bioinformatics research, but there is almost rarely clear mechanism research or clinical diagnosis to support these results; Therefore, it is necessary to continue studying the role of snoRNA in CVDs. Advancements in modern molecular technology will be conducive to a comprehensive and in-depth study of the mechanism of snoRNAs in CVDs. snoRNAs are highly likely to become biomarkers and targets for CVDs diagnosis, intervention, and prognosis, thus providing new viewpoints and directions for the monitoring and treatment of CVDs. Therefore, future snoRNA research focusing on these fields deserves deeper investigation and needs increased research efforts.

6.1 Search strategy and selection criteria

All keywords of the searched literature: small nucleolar RNA, snoRNA, SNORD, SNORA, non-coding RNA, ncRNA, RNA, cardiovascular disease, CVD, heart, cardiac, cardiometabolic disease, CMD, congenital heart disease, CHD, congenital heart defect, coronary heart disease, Myocardial infarction, MI, heart failure, HF, vascular remodeling, peripheral artery disease, PAD, Hypertrophic cardiomyopathy, HCM, RNA-seq, RNA-seq sequencing, transcriptomics.

 Author contributions

XS: Conceptualization, Writing–original draft, Writing–review and editing. GW: Supervision, Writing–review and editing. WL: Investigation, Writing–review and editing. HG: Investigation, Writing–review and editing. WM: Writing–review and editing. XW: Investigation, Writing–review and editing. DL: Investigation, Writing–review and editing. SJ: Investigation, Writing–review and editing. SC: Investigation, Writing–review and editing. YW: Writing–review and editing. ZY: Conceptualization, Funding acquisition, Supervision, Writing–review and editing.

 Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Key Research and Development Program (2021YFC2701003 and 2021YFC2701104), the National Natural Science Foundation of China (82171649 and 81871219), the LiaoNing Revitalization Talents Program (XLYC1902099), the Liaoning Province Applied Basic Research Program (2022JH2/101500001) and the 345 Talent Project of Shengjing Hospital.

Figures 2, 3 was created by Figdraw.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Amri E. Z. Scheideler M. (2017). Small non coding RNAs in adipocyte biology and obesity. Mol. Cell. Endocrinol. 456, 87–94. 10.1016/j.mce.2017.04.009 Ash-Bernal R. Peterson L. R. (2006). The cardiometabolic syndrome and cardiovascular disease. J. Cardiometab Syndr. 1, 25–28. 10.1111/j.0197-3118.2006.05452.x Baldini L. Charpentier B. Labialle S. (2021). Emerging data on the diversity of molecular mechanisms involving C/D snoRNAs. Noncoding RNA 7. 10.3390/ncrna7020030 Beneventi G. Munita R. Cao Thi Ngoc P. Madej M. Ciesla M. Muthukumar S. (2021). The small Cajal body-specific RNA 15 (SCARNA15) directs p53 and redox homeostasis via selective splicing in cancer cells. Nar. Cancer 3, zcab026. 10.1093/narcan/zcab026 Bergeron D. Fafard-Couture É. Scott M. S. (2020). Small nucleolar RNAs: continuing identification of novel members and increasing diversity of their molecular mechanisms of action. Biochem. Soc. Trans. 48, 645–656. 10.1042/bst20191046 Bergeron D. Paraqindes H. Fafard-Couture É. Deschamps-Francoeur G. Faucher-Giguère L. Bouchard-Bourelle P. (2023). snoDB 2.0: an enhanced interactive database, specializing in human snoRNAs. Nucleic acids Res. 51, D291–D296. 10.1093/nar/gkac835 Berkeley B. Tang M. N. H. Brittan M. (2023). Mechanisms regulating vascular and lymphatic regeneration in the heart after myocardial infarction. J. pathology 260, 666–678. 10.1002/path.6093 Borchardt E. K. Martinez N. M. Gilbert W. V. (2020). Regulation and function of RNA pseudouridylation in human cells. Annu. Rev. Genet. 54, 309–336. 10.1146/annurev-genet-112618-043830 Bortolin-Cavaille M. L. Quillien A. Thalalla Gamage S. Thomas J. M. Sas-Chen A. Sharma S. (2022). Probing small ribosomal subunit RNA helix 45 acetylation across eukaryotic evolution. Nucleic Acids Res. 50, 6284–6299. 10.1093/nar/gkac404 Boudoulas K. D. Triposciadis F. Geleris P. Boudoulas H. (2016). Coronary atherosclerosis: pathophysiologic basis for diagnosis and management. Prog. Cardiovasc. Dis. 58, 676–692. 10.1016/j.pcad.2016.04.003 Brandis K. A. Gale S. Jinn S. Langmade S. J. Dudley-Rucker N. Jiang H. (2013). Box C/D small nucleolar RNA (snoRNA) U60 regulates intracellular cholesterol trafficking. J. Biol. Chem. 288, 35703–35713. 10.1074/jbc.M113.488577 Bratkovic T. Bozic J. Rogelj B. (2020). Functional diversity of small nucleolar RNAs. Nucleic Acids Res. 48, 1627–1651. 10.1093/nar/gkz1140 Çakmak H. A. Demir M. (2020). MicroRNA and cardiovascular diseases. Balk. Med. J. 37, 60–71. 10.4274/balkanmedj.galenos.2020.2020.1.94 Campia U. Gerhard-Herman M. Piazza G. Goldhaber S. Z. (2019). Peripheral artery disease: past, present, and future. Am. J. Med. 132, 1133–1141. 10.1016/j.amjmed.2019.04.043 Cao T. Rajasingh S. Samanta S. Dawn B. Bittel D. C. Rajasingh J. (2018). Biology and clinical relevance of noncoding sno/scaRNAs. Trends Cardiovasc Med. 28, 81–90. 10.1016/j.tcm.2017.08.002 Cao M. Zhao J. Hu G. (2019). Genome-wide methods for investigating long noncoding RNAs. Biomed. Pharmacother. 111, 395–401. 10.1016/j.biopha.2018.12.078 Caton E. A. Kelly E. K. Kamalampeta R. Kothe U. (2018). Efficient RNA pseudouridylation by eukaryotic H/ACA ribonucleoproteins requires high affinity binding and correct positioning of guide RNA. Nucleic Acids Res. 46, 905–916. 10.1093/nar/gkx1167 Chen R. Shi C. Yao J. Chen W. (2020). Online databases and non-coding RNAs in cardiovascular diseases. Adv. Exp. Med. Biol. 1229, 65–78. 10.1007/978-981-15-1671-9_3 Chen S. Li Q. H. Chen X. Bao H. J. Wu W. Shen F. (2022). SNORA70E promotes the occurrence and development of ovarian cancer through pseudouridylation modification of RAP1B and alternative splicing of PARPBP. J. Cell. Mol. Med. 26, 5150–5164. 10.1111/jcmm.17540 Coley A. B. DeMeis J. D. Chaudhary N. Y. Borchert G. M. (2022a). Small nucleolar derived RNAs as regulators of human cancer. Biomedicines 10. 10.3390/biomedicines10081819 Coley A. B. Stahly A. N. Kasukurthi M. V. Barchie A. A. Hutcheson S. B. Houserova D. (2022b). MicroRNA-like snoRNA-derived RNAs (sdRNAs) promote castration-resistant prostate cancer. Cells 11, 1302. 10.3390/cells11081302 Das S. Shah R. Dimmeler S. Freedman J. E. Holley C. Lee J. M. (2020). Noncoding RNAs in cardiovascular disease: current knowledge, tools and technologies for investigation, and future directions: a scientific statement from the American heart association. Circulation-Genomic Precis. Med. 13, e000062. 10.1161/HCG.0000000000000062 Dennis P. P. Tripp V. Lui L. Lowe T. Randau L. (2015). C/D box sRNA-guided 2'-O-methylation patterns of archaeal rRNA molecules. BMC Genomics 16, 632. 10.1186/s12864-015-1839-z Deryusheva S. Gall J. G. (2013). Novel small Cajal-body-specific RNAs identified in Drosophila: probing guide RNA function. RNA 19, 1802–1814. 10.1261/rna.042028.113 Desai M. Y. Owens A. Wang A. (2023). Medical therapies for hypertrophic cardiomyopathy: current state of the art. Prog. Cardiovasc. Dis. 80, 32–37. 10.1016/j.pcad.2023.08.006 Diermeier S. D. Schubert T. Langst G. (2014). Deep sequencing of small chromatin-associated RNA: isolation and library preparation. Methods Mol. Biol. 1094, 343–353. 10.1007/978-1-62703-706-8_27 Ding Y. Sun Z. Q. Zhang S. T. Li Y. J. Han X. Xu Q. H. (2021). Downregulation of snoRNA SNORA52 and its clinical significance in hepatocellular carcinoma. Biomed Res. Int. 2021, 7020637. 10.1155/2021/7020637 Dudnakova T. Dunn-Davies H. Peters R. Tollervey D. (2018). Mapping targets for small nucleolar RNAs in yeast. Wellcome Open Res. 3, 120. 10.12688/wellcomeopenres.14735.2 Ender C. Krek A. Friedlander M. R. Beitzinger M. Weinmann L. Chen W. (2008). A human snoRNA with MicroRNA-like functions. Mol. Cell 32, 519–528. 10.1016/j.molcel.2008.10.017 Fafard-Couture É. Bergeron D. Couture S. Abou-Elela S. Scott M. S. (2021). Annotation of snoRNA abundance across human tissues reveals complex snoRNA-host gene relationships. Genome Biol. 22, 172. 10.1186/s13059-021-02391-2 Falaleeva M. Pages A. Matuszek Z. Hidmi S. Agranat-Tamir L. Korotkov K. (2016). Dual function of C/D box small nucleolar RNAs in rRNA modification and alternative pre-mRNA splicing. Proc. Natl. Acad. Sci. U. S. A. 113, E1625–E1634. 10.1073/pnas.1519292113 Fasolo F. Di Gregoli K. Maegdefessel L. Johnson J. L. (2019). Non-coding RNAs in cardiovascular cell biology and atherosclerosis. Cardiovasc. Res. 115, 1732–1756. 10.1093/cvr/cvz203 Galiveti C. R. Rozhdestvensky T. S. Brosius J. Lehrach H. Konthur Z. (2010). Application of housekeeping npcRNAs for quantitative expression analysis of human transcriptome by real-time PCR. RNA (New York, N.Y.). 16, 450–461. 10.1261/rna.1755810 Garus A. Autexier C. (2021). Dyskerin: an essential pseudouridine synthase with multifaceted roles in ribosome biogenesis, splicing, and telomere maintenance. RNA 27, 1441–1458. 10.1261/rna.078953.121 Gong J. Li Y. Liu C. J. Xiang Y. Li C. Ye Y. (2017). A pan-cancer analysis of the expression and clinical relevance of small nucleolar RNAs in human cancer. Cell Rep. 21, 1968–1981. 10.1016/j.celrep.2017.10.070 Gong X. Tian M. Cao N. A. Yang P. L. Xu Z. C. Zheng S. (2021). Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation. J. Clin. Investigation 131, e147031. 10.1172/JCI147031 Håkansson K. E. J. Sollie O. Simons K. H. Quax P. H. A. Jensen J. Nossent A. Y. (2018). Circulating small non-coding RNAs as biomarkers for recovery after exhaustive or repetitive exercise. Front. Physiol. 9, 1136. 10.3389/fphys.2018.01136 Hakansson K. E. J. Goossens E. A. C. Trompet S. van Ingen E. de Vries M. R. van der Kwast (2019). Genetic associations and regulation of expression indicate an independent role for 14q32 snoRNAs in human cardiovascular disease. Cardiovasc Res. 115, 1519–1532. 10.1093/cvr/cvy309 Han C. Sun L. Y. Luo X. Q. Pan Q. Sun Y. M. Zeng Z. C. (2022). Chromatin-associated orphan snoRNA regulates DNA damage-mediated differentiation via a non-canonical complex. Cell Rep. 38, 110421. 10.1016/j.celrep.2022.110421 He X. X. Chen X. Zhang X. Duan X. B. Pan T. Hu Q. F. (2015). An Lnc RNA (GAS5)/SnoRNA-derived piRNA induces activation of TRAIL gene by site-specifically recruiting MLL/COMPASS-like complexes. Nucleic Acids Res. 43, 3712–3725. 10.1093/nar/gkv214 Heraud-Farlow J. E. Walkley C. R. (2020). What do editors do? Understanding the physiological functions of A-to-I RNA editing by adenosine deaminase acting on RNAs. Open Biol. 10, 200085. 10.1098/rsob.200085 Hiatt W. R. Goldstone J. Smith S. C. McDermott M. Moneta G. Oka R. (2008). Atherosclerotic peripheral vascular disease symposium II nomenclature for vascular diseases. Circulation 118, 2826–2829. 10.1161/Circulationaha.108.191171 Holley C. L. Li M. W. Scruggs B. S. Matkovich S. J. Ory D. S. Schaffer J. E. (2015). Cytosolic accumulation of small nucleolar RNAs (snoRNAs) is dynamically regulated by NADPH oxidase. J. Biol. Chem. 290, 11741–11748. 10.1074/jbc.M115.637413 Huang C. Shi J. Guo Y. Huang W. Huang S. Ming S. (2017). A snoRNA modulates mRNA 3' end processing and regulates the expression of a subset of mRNAs. Nucleic Acids Res. 45, 8647–8660. 10.1093/nar/gkx651 Huang W W. Sun Y. M. Pan Q. Fang K. Chen X. T. Zeng Z. C. (2022). The snoRNA-like lncRNA LNC-SNO49AB drives leukemia by activating the RNA-editing enzyme ADAR1. Cell Discov. 8, 117. 10.1038/s41421-022-00460-9 Huang Z H Z. H. Du Y. P. Wen J. T. Lu B. F. Zhao Y. (2022). snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology. Cell Death Discov. 8, 259. 10.1038/s41420-022-01056-8 Jackman J. E. Alfonzo J. D. (2013). Transfer RNA modifications: nature's combinatorial chemistry playground. Wiley Interdiscip. Rev. RNA 4, 35–48. 10.1002/wrna.1144 James V. Nizamudeen Z. A. Lea D. Dottorini T. Holmes T. L. Johnson B. B. (2021). Transcriptomic analysis of cardiomyocyte extracellular vesicles in hypertrophic cardiomyopathy reveals differential snoRNA cargo. Stem Cells Dev. 30, 1215–1227. 10.1089/scd.2021.0202 Jin G. H. Xu M. Q. Zou M. S. Duan S. W. (2020). The processing, gene regulation, biological functions, and clinical relevance of N4-acetylcytidine on RNA: a systematic review. Mol. Therapy-Nucleic Acids. 20, 13–24. 10.1016/j.omtn.2020.01.037 Jinn S. Brandis K. A. Ren A. Chacko A. Dudley-Rucker N. Gale S. E. (2015). snoRNA U17 regulates cellular cholesterol trafficking. Cell Metab. 21, 855–867. 10.1016/j.cmet.2015.04.010 Killick R. Stranks L. Hoyos C. M. (2022). Sleep deficiency and cardiometabolic disease. Clin. Chest Med. 43, 319–336. 10.1016/j.ccm.2022.02.011 Kim D. S. Camacho C. V. Nagari A. Malladi V. S. Challa S. Kraus W. L. (2019). Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21. Mol. Cell 75, 1270–1285 e1214. 10.1016/j.molcel.2019.06.020 Kim C. W. Aronow W. S. Frishman W. H. (2022). Coronavirus disease 2019 and cardiometabolic disease. Cardiol. Rev. 30, 123–128. 10.1097/Crd.0000000000000405 Kim R. W. (2021). Is there any clinical utility to genetic testing for patients with congenital heart disease? Semin. Thorac. Cardiovasc Surg. Pediatr. Card. Surg. Annu. 24, 26–29. 10.1053/j.pcsu.2021.04.002 King T. H. Liu B. McCully R. R. Fournier M. J. (2003). Ribosome structure and activity are altered in cells lacking snoRNPs that form pseudouridines in the peptidyl transferase center. Mol. Cell 11, 425–435. 10.1016/s1097-2765(03)00040-6 Kishore S. Khanna A. Zhang Z. Hui J. Balwierz P. J. Stefan M. (2010). The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum. Mol. Genet. 19, 1153–1164. 10.1093/hmg/ddp585 Kocher M. A. Huang F. W. Le E. Good D. J. (2021). Snord116 post-transcriptionally increases Nhlh2 mRNA stability: implications for human prader-willi syndrome. Hum. Mol. Genet. 30, 1101–1110. 10.1093/hmg/ddab103 Kruszka P. Beaton A. (2020). The state of congenital heart disease. Am. J. Med. Genet. C Semin. Med. Genet. 184 (1), 5–6. 10.1002/ajmg.c.31776 Kumar A. Clerici M. Muckenfuss L. M. Passmore L. A. Jinek M. (2019). Mechanistic insights into mRNA 3'-end processing. Curr. Opin. Struct. Biol. 59, 143–150. 10.1016/j.sbi.2019.08.001 Lafaille F. G. Harschnitz O. Lee Y. S. Zhang P. Hasek M. L. Kerner G. (2019). Human SNORA31 variations impair cortical neuron-intrinsic immunity to HSV-1 and underlie herpes simplex encephalitis. Nat. Med. 25, 1873–1884. 10.1038/s41591-019-0672-3 Lam C. S. P. Docherty K. F. Ho J. E. McMurray J. J. V. Myhre P. L. Omland T. (2023). Recent successes in heart failure treatment. Nat. Med. 29, 2424. [published online ahead of print, 2023 Oct 9]. 10.1038/s41591-023-02567-2 Lee J. Y. Harris A. N. Holley C. L. Mahadevan J. Pyles K. D. Lavagnino Z. (2016). Rpl13a small nucleolar RNAs regulate systemic glucose metabolism. J. Clin. Investigation 126, 4616–4625. 10.1172/Jci88069 Leung S. K. Jeffries A. R. Castanho I. Jordan B. T. Moore K. Davies J. P. (2021). Full-length transcript sequencing of human and mouse cerebral cortex identifies widespread isoform diversity and alternative splicing. Cell Rep. 37, 110022. 10.1016/j.celrep.2021.110022 Li J. J. H. Wu Z. N. Zheng D. Q. Sun Y. Wang S. S. Yan Y. (2019). Bioinformatics analysis of the regulatory lncRNA-miRNA-mRNA network and drug prediction in patients with hypertrophic cardiomyopathy. Mol. Med. Rep. 20, 549–558. 10.3892/mmr.2019.10289 Li C. Wu L. Liu P. Li K. Zhang Z. He Y. (2020). The C/D box small nucleolar RNA SNORD52 regulated by Upf1 facilitates Hepatocarcinogenesis by stabilizing CDK1. Theranostics 10, 9348–9363. 10.7150/thno.47677 Li M M. Yang Y. Wang Z. Zong T. Fu X. Aung L. H. H. (2021). Piwi-interacting RNAs (piRNAs) as potential biomarkers and therapeutic targets for cardiovascular diseases. Angiogenesis 24, 19–34. 10.1007/s10456-020-09750-w Li X X. Peng J. Yi C. (2021). The epitranscriptome of small non-coding RNAs. Noncoding RNA Res. 6, 167–173. 10.1016/j.ncrna.2021.10.002 Liang B. Li H. (2011). Structures of ribonucleoprotein particle modification enzymes. Q. Rev. Biophys. 44, 95–122. 10.1017/S0033583510000235 Liao J. Yu L. Mei Y. Guarnera M. Shen J. Li R. (2010). Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol. Cancer 9, 198. 10.1186/1476-4598-9-198 Lim T. B. Lavenniah A. Foo R. S. (2020). Circles in the heart and cardiovascular system. Cardiovasc Res. 116 (2), 269–278. 10.1093/cvr/cvz227 Lu Z. Zhang Q. C. Lee B. Flynn R. A. Smith M. A. Robinson J. T. (2016). RNA duplex map in living cells reveals higher-order transcriptome structure. Cell 165, 1267–1279. 10.1016/j.cell.2016.04.028 Massenet S. Bertrand E. Verheggen C. (2017). Assembly and trafficking of box C/D and H/ACA snoRNPs. RNA Biol. 14 (6), 680–692. 10.1080/15476286.2016 Mensah G. A. Roth G. A. Fuster V. (2019). The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J. Am. Coll. Cardiol. 74, 2529–2532. 10.1016/j.jacc.2019.10.009 Michel C. I. Holley C. L. Scruggs B. S. Sidhu R. Brookheart R. T. Listenberger L. L. (2011). Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. Cell Metab. 14, 33–44. 10.1016/j.cmet.2011.04.009 Mick E. Shah R. Tanriverdi K. Murthy V. Gerstein M. Rozowsky J. (2017). Stroke and circulating extracellular RNAs. Stroke 48, 828–834. 10.1161/STROKEAHA.116.015140 Monaco P. L. Marcel V. Diaz J. J. Catez F. (2018). 2'-O-Methylation of ribosomal RNA: towards an epitranscriptomic control of translation? Biomolecules 8, 106. 10.3390/biom8040106 Morgenthau A. Frishman W. H. (2018). Genetic origins of tetralogy of Fallot. Cardiol. Rev. 26, 86–92. 10.1097/crd.0000000000000170 Morton S. U. Quiat D. Seidman J. G. Seidman C. E. (2022). Genomic frontiers in congenital heart disease. Nat. Rev. Cardiol. 19, 26–42. 10.1038/s41569-021-00587-4 Mourksi N. E. H. Morin C. Fenouil T. Diaz J. J. Marcel V. (2020). snoRNAs offer novel insight and promising perspectives for lung cancer understanding and management. Cells 9, 541. 10.3390/cells9030541 Nagasawa C. Ogren A. Kibiryeva N. Marshall J. O'Brien J. E. Kenmochi N. (2018). The role of scaRNAs in adjusting alternative mRNA splicing in heart development. J. Cardiovasc. Dev. Dis. 5, 26. 10.3390/jcdd5020026 Nagasawa C. K. Kibiryeva N. Marshall J. O'Brien J. E. Bittel D. C. (2020). scaRNA1 levels alter pseudouridylation in spliceosomal RNA U2 affecting alternative mRNA splicing and embryonic development. Pediatr. Cardiol. 41, 341–349. 10.1007/s00246-019-02263-4 Niescierowicz K. Pryszcz L. Navarrete C. Tralle E. Sulej A. Abu Nahia K. (2022). Adar-mediated A-to-I editing is required for embryonic patterning and innate immune response regulation in zebrafish. Nat. Commun. 13, 5520. 10.1038/s41467-022-33260-6 Nilsen T. W. Graveley B. R. (2010). Expansion of the eukaryotic proteome by alternative splicing. Nature 463, 457–463. 10.1038/nature08909 Nossent A. Y. Ektefaie N. Wojta J. Eichelberger B. Kopp C. Panzer S. (2019). Plasma levels of snoRNAs are associated with platelet activation in patients with peripheral artery disease. Int. J. Mol. Sci. 20, 5975. 10.3390/ijms20235975 Nostramo R. T. Hopper A. K. (2019). Beyond rRNA and snRNA: tRNA as a 2 '-O-methylation target for nucleolar and Cajal body box C/D RNPs. Genes & Dev. 33, 739–740. 10.1101/gad.328443.119 O'Brien J. E. Jr. Kibiryeva N. Zhou X. G. Marshall J. A. Lofland G. K. Artman M. (2012). Noncoding RNA expression in myocardium from infants with tetralogy of Fallot. Circ. Cardiovasc Genet. 5, 279–286. 10.1161/CIRCGENETICS.111.961474 Ogren A. Kibiryeva N. Marshall J. O'Brien J. E. Jr. Bittel D. C. (2019). Snord94 expression level alters methylation at C62 in snRNA U6. PLoS One 14, e0226035. 10.1371/journal.pone.0226035 Okugawa Y. Toiyama Y. Toden S. Mitoma H. Nagasaka T. Tanaka K. (2017). Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Gut 66, 107–117. 10.1136/gutjnl-2015-309359 Ottaviani A. Mansour D. Molinari L. V. Galanti K. Mantini C. Khanji M. Y. (2023). Revisiting diagnosis and treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. J. Clin. Med. 12, 5710. 10.3390/jcm12175710 Pan Q. Shai O. Lee L. J. Frey J. Blencowe B. J. (2008). Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413–1415. 10.1038/ng.259 Patil P. Kibiryeva N. Uechi T. Marshall J. O'Brien J. E. Artman M. (2015). scaRNAs regulate splicing and vertebrate heart development. Biochimica Biophysica Acta-Molecular Basis Dis. 1852, 1619–1629. 10.1016/j.bbadis.2015.04.016 Poller W. Dimmeler S. Heymans S. Zeller T. Haas J. Karakas M. (2018). Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur. Heart J. 39, 2704. 10.1093/eurheartj/ehx165 Rajan K. S. Ramasamy S. George-William J. N. Rajendhran J. (2017). Emerging cardiac non-coding landscape: the importance of meta-analysis. Biochimie 133, 87–94. 10.1016/j.biochi.2016.12.01 Rimer J. M. Lee J. Holley C. L. Crowder R. J. Chen D. L. Hanson P. I. (2018). Long-range function of secreted small nucleolar RNAs that direct 2 '-O-methylation. J. Biol. Chem. 293, 13284–13296. 10.1074/jbc.RA118.003410 Roth G. A. Mensah G. A. Fuster V. (2020). The global burden of cardiovascular diseases and risks: a compass for global action. J. Am. Coll. Cardiol. 76, 2980–2981. 10.1016/j.jacc.2020.11.021 Samad T. Wu S. M. (2021). Single cell RNA sequencing approaches to cardiac development and congenital heart disease. Semin. Cell Dev. Biol. 118, 129–135. 10.1016/j.semcdb.2021.04.023 Schaffer J. E. (2020). Death by lipids: the role of small nucleolar RNAs in metabolic stress. J. Biol. Chem. 295, 8628–8635. 10.1074/jbc.AW120.011105 Schena G. J. Murray E. K. Hildebrand A. N. Headrick A. L. Yang Y. Koch K. A. (2021). Cortical bone stem cell-derived exosomes' therapeutic effect on myocardial ischemia-reperfusion and cardiac remodeling. Am. J. Physiol. Heart Circ. Physiol. 321, H1014–h1029. 10.1152/ajpheart.00197.2021 Schubert T. Pusch M. C. Diermeier S. Benes V. Kremmer E. Imhof A. (2012). Df31 protein and snoRNAs maintain accessible higher-order structures of chromatin. Mol. Cell 48, 434–444. 10.1016/j.molcel.2012.08.021 Seidelmann S. B. Lighthouse J. K. Greif D. M. (2014). Development and pathologies of the arterial wall. Cell Mol. Life Sci. 71, 1977–1999. 10.1007/s00018-013-1478-y Shahzadi S. K. Naidoo N. Alsheikh-Ali A. Rizzo M. Rizvi A. A. Santos R. D. (2021). Reconnoitering the role of long-noncoding RNAs in hypertrophic cardiomyopathy: a descriptive review. Int. J. Mol. Sci. 22, 9378. 10.3390/ijms22179378 Sharma S. Langhendries J. L. Watzinger P. Kotter P. Entian K. D. Lafontaine D. L. J. (2015). Yeast Kre33 and human NAT10 are conserved 18S rRNA cytosine acetyltransferases that modify tRNAs assisted by the adaptor Tan1/THUMPD1. Nucleic Acids Res. 43, 2242–2258. 10.1093/nar/gkv075 Sharma S. Yang J. van Nues R. Watzinger P. Kotter P. Lafontaine D. L. J. (2017). Specialized box C/D snoRNPs act as antisense guides to target RNA base acetylation. Plos Genet. 13, e1006804. 10.1371/journal.pgen.1006804 Slack F. J. Chinnaiyan A. M. (2019). The role of non-coding RNAs in oncology. Cell 179, 1033–1055. 10.1016/j.cell.2019.10.017 Sletten A. C. Davidson J. W. Yagabasan B. Moores S. Schwaiger-Haber M. Fujiwara H. (2021). Loss of SNORA73 reprograms cellular metabolism and protects against steatohepatitis. Nat. Commun. 12, 5214. 10.1038/s41467-021-25457-y Smani T. Mayoral-Gonzalez I. Galeano-Otero I. Gallardo-Castillo I. Rosado J. A. Ordoñez A. (2020). Non-coding RNAs and ischemic cardiovascular diseases. Adv. Exp. Med. Biol. 1229, 259–271. 10.1007/978-981-15-1671-9_15 Stepanov G. A. Filippova J. A. Komissarov A. B. Kuligina E. V. Richter V. A. Semenov D. V. (2015). Regulatory role of small nucleolar RNAs in human diseases. Biomed. Res. Int. 2015, 206849. 10.1155/2015/20684 Tallo C. A. Duncan L. H. Yamamoto A. H. Slaydon J. D. Arya G. H. Turlapati L. (2021). Heat shock proteins and small nucleolar RNAs are dysregulated in a Drosophila model for feline hypertrophic cardiomyopathy. G3-Genes Genomes Genet. 11, jkaa014. 10.1093/g3journal/jkaa014 Tang Y. Bao J. H. Hu J. H. Liu L. L. Xu D. Y. (2021). Circular RNA in cardiovascular disease: expression, mechanisms and clinical prospects. J. Cell. Mol. Med. 25, 1817–1824. 10.1111/jcmm.16203 Trucks S. Hanspach G. Hengesbach M. (2021). Eukaryote specific RNA and protein features facilitate assembly and catalysis of H/ACA snoRNPs. Nucleic Acids Res. 49, 4629–4642. 10.1093/nar/gkab177 van Ingen E. Engbers P. A. M. Woudenberg T. van der Bent M. L. Mei H. L. Wojta J. (2022a). C/D box snoRNA SNORD113-6 guides 2'-O- methylation and protects against site-specific fragmentation of tRNALeu(TAA) in vascular remodeling. Mol. Therapy-Nucleic Acids. 30, 162–172. 10.1016/j.omtn.2022.09.011 van Ingen E. van den Homberg D. A. L. van der Bent M. L. Mei H. L. Papac-Milicevic N. Kremer V. (2022b). C/D box snoRNA SNORD113-6/AF357425 plays a dual role in integrin signalling and arterial fibroblast function via pre-mRNA processing and 2 ' O-ribose methylation. Hum. Mol. Genet. 31, 1051–1066. 10.1093/hmg/ddab304 Vitali P. Kiss T. (2019). Cooperative 2'-O-methylation of the wobble cytidine of human elongator tRNA(Met)(CAT) by a nucleolar and a Cajal body-specific box C/D RNP. Genes Dev. 33, 741–746. 10.1101/gad.326363.119 Wajahat M. Bracken C. P. Orang A. (2021). Emerging functions for snoRNAs and snoRNA-derived fragments. Int. J. Mol. Sci. 22, 10193. 10.3390/ijms221910193 Wang B. Zhao Y. Li Y. Xu Y. Chen Y. Jiang Q. (2022). A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients. Mol. Cancer 21, 22. 10.1186/s12943-022-01504-0 Watson C. N. Belli A. Di Pietro V. (2019). Small non-coding RNAs: new class of biomarkers and potential therapeutic targets in neurodegenerative disease. Front. Genet. 10, 364. 10.3389/fgene.2019.00364 Wei P. Wang H. Li Y. Guo R. (2021). Nucleolar small molecule RNA SNORA75 promotes endometrial receptivity by regulating the function of miR-146a-3p and ZNF23. Aging (Albany NY) 13, 14924–14939. 10.18632/aging.203007 Welten S. M. Goossens E. A. Quax P. H. Nossent A. Y. (2016). The multifactorial nature of microRNAs in vascular remodelling. Cardiovasc Res. 110, 6–22. 10.1093/cvr/cvw039 Williams K. Carson J. Lo C. (2019). Genetics of congenital heart disease. Biomolecules 9, 879. 10.3390/biom9120879 Wu H. Yin Q. F. Luo Z. Yao R. W. Zheng C. C. Zhang J. (2016). Unusual processing generates SPA LncRNAs that sequester multiple RNA binding proteins. Mol. Cell 64, 534–548. 10.1016/j.molcel.2016.10.007 Wu F. Zhang L. Wu P. Wu Y. Zhang T. Zhang D. (2022). The potential role of small nucleolar RNAs in cancers - an evidence map. Int. J. Gen. Med. 15, 3851–3864. 10.2147/IJGM.S352333 Xu W. Wu Y. Fang X. Zhang Y. Cai N. Wen J. (2021). SnoRD126 promotes the proliferation of hepatocellular carcinoma cells through transcriptional regulation of FGFR2 activation in combination with hnRNPK. Aging (Albany NY) 13, 13300–13317. 10.18632/aging.203014 Yang Y. X. Okada S. Sakurai M. (2021). Adenosine-to-inosine RNA editing in neurological development and disease. Rna Biol. 18, 999–1013. 10.1080/15476286.2020.1867797 Yin L. L. Tang Y. H. Jiang M. H. (2021). Research on the circular RNA bioinformatics in patients with acute myocardial infarction. J. Clin. Laboratory Analysis 35, e23621. 10.1002/jcla.23621 Yin L. Tang Y. Yuan Y. (2022). An overview of the advances in research on the molecular function and specific role of circular RNA in cardiovascular diseases. Biomed. Res. Int. 2022, 5154122. 10.1155/2022/5154122 Yu G. Zhao Y. Li H. (2018). The multistructural forms of box C/D ribonucleoprotein particles. RNA 24, 1625–1633. 10.1261/rna.068312.118 Zeng Z. D. Zhang H. W. Liu F. L. Zhang N. (2016). Current diagnosis and treatments for critical congenital heart defects. Exp. Ther. Med. 11, 1550–1554. 10.3892/etm.2016.3167 Zhu L. Li N. Sun L. Zheng D. Shao G. (2021). Non-coding RNAs: the key detectors and regulators in cardiovascular disease. Genomics 113, 1233–1246. 10.1016/j.ygeno.2020.10.024 Zhu W. J. Zhang T. Luan S. H. Kong Q. N. Hu W. M. Zou X. (2022). Identification of a novel nine-SnoRNA signature with potential prognostic and therapeutic value in ovarian cancer. Cancer Med. 11, 2159–2170. 10.1002/cam4.4598